Boros Eszter, Dyson Paul J, Gasser Gilles
Department of Chemistry, Stony Brook University, 100 Nicolls road, Stony Brook, New York, NY 11790, USA.
Institut des Sciences et Ingénierie Chimiques, Ecole Polytechnique Fédérale de Lausanne (EPFL), 1015 Lausanne, Switzerland.
Chem. 2020 Jan 9;6(1):41-60. doi: 10.1016/j.chempr.2019.10.013. Epub 2019 Nov 7.
Metal-based drugs and imaging agents are extensively used in the clinic for the treatment and diagnosis of cancers and a wide range of other diseases. The current clinical arsenal of compounds operate via a limited number of mechanisms, whereas new putative compounds explore alternative mechanisms of action, which could potentially bring new chemotherapeutic approaches into the clinic. In this review, metal-based drugs and imaging agents are characterized according to their primary mode of action and the key properties and features of each class of compounds are defined, wherever possible. A better understanding of the roles played by metal compounds at a mechanistic level will help to deliver new metal-based therapies to the clinic, by providing an alternative, targeted and rational approach, to supplement non-targeted screening of novel chemical entities for biological activity.
金属基药物和成像剂在临床上被广泛用于癌症及多种其他疾病的治疗和诊断。目前临床使用的化合物库通过有限的几种机制发挥作用,而新的潜在化合物则探索其他作用机制,这有可能为临床带来新的化疗方法。在本综述中,金属基药物和成像剂根据其主要作用模式进行了表征,并尽可能定义了每类化合物的关键特性和特征。从机制层面更好地理解金属化合物所起的作用,将有助于通过提供一种替代的、有针对性的合理方法,将新的金属基疗法引入临床,以补充对新型化学实体进行生物活性的非靶向筛选。